Year: 2023

Amicus Therapeutics to Present at Upcoming Investor Conferences in November 2023

Written by Customer Service on November 1, 2023. Posted in Public Companies.

PRINCETON, N.J., Nov. 01, 2023 (GLOBE NEWSWIRE) — Amicus Therapeutics (Nasdaq: FOLD) today announced that management will participate in upcoming presentations at the following investor conferences in November.UBS Biopharma Conference in Miami, FL on Thursday, November 9, 2023, at 1:00 p.m. E.T. Stifel 2023 Healthcare Conference in New York, NY on Wednesday, November 15, 2023, at 8:00 a.m. E.T.A live audio webcast of each presentation can also be accessed via the investors section of the Amicus Therapeutics corporate website at https://ir.amicusrx.com/events-and-presentations. About Amicus Therapeutics Amicus Therapeutics (Nasdaq: FOLD) is a global, patient-dedicated biotechnology company focused on discovering, developing and delivering novel high-quality medicines for people living with rare diseases. With extraordinary patient...

Monopar Presents Data Showing Tumor Reduction Benefit of Camsirubicin from Ongoing Phase 1b at the 2023 Connective Tissue Oncology Society (CTOS) Annual Meeting

Written by Customer Service on November 1, 2023. Posted in Public Companies.

WILMETTE, Ill., Nov. 01, 2023 (GLOBE NEWSWIRE) — Monopar Therapeutics Inc. (Nasdaq: MNPR), a clinical-stage biopharmaceutical company focused on developing proprietary therapeutics designed to extend life or improve the quality of life for cancer patients, will present data from its ongoing Phase 1b open-label, dose-escalating clinical trial of camsirubicin in patients with advanced soft tissue sarcoma (ASTS) later today at the 2023 Connective Tissue Oncology Society (CTOS) Annual Meeting, which is bringing together the world’s leading sarcoma specialists. Monopar’s poster presentation can be found at the following link: https://www.monopartx.com/pipeline/Camsirubicin/mnpr-201-001-clinical-trial. Clinical Trial Results To-Date The Phase 1b clinical trial has enrolled 14 ASTS patients (9 female and 5 male) to-date ranging in age...

Atea Pharmaceuticals to Host Third Quarter 2023 Financial Results Conference Call on November 8, 2023

Written by Customer Service on November 1, 2023. Posted in Public Companies.

BOSTON, Nov. 01, 2023 (GLOBE NEWSWIRE) — Atea Pharmaceuticals, Inc. (Nasdaq: AVIR) (“Atea”), a clinical-stage biopharmaceutical company engaged in the discovery and development of oral antiviral therapeutics for serious viral diseases, today announced that it will host a live conference call and audio webcast on Wednesday, November 8, 2023, at 4:30 p.m. ET to report financial results for the third quarter ended September 30, 2023, and to provide a business update. To access the live conference call, participants may register here. The live audio webcast of the call will be available under “Events and Presentations” in the Investor Relations section of the Atea Pharmaceuticals website at ir.ateapharma.com. To participate via telephone, please register in advance here. Upon registration, all telephone participants will...

StateHouse Issues Consideration for Increased Interest In Haight-Ashbury Dispensary

Written by Customer Service on November 1, 2023. Posted in Mergers And Acquisitions.

SAN DIEGO and TORONTO, Nov. 01, 2023 (GLOBE NEWSWIRE) — StateHouse Holdings Inc. (“StateHouse” or the “Company”) (CSE: STHZ) (OTCQB: STHZF), a California-focused, vertically integrated cannabis company, today announced that the Company has completed the issuance of shares related to its acquisition of a further 29.9% interest in FGW Haight, Inc. (“FGW” or “Harborside San Francisco”), a cannabis dispensary in San Francisco’s historic Haight-Ashbury district (the “FGW Acquisition”), as previously announced on February 15, 2022. The FGW Acquisition has increased the Company’s interest in Harborside San Francisco to 80%. Since its grand opening on May 21, 2022, Harborside San Francisco has participated in a variety of community engagement activities, including:Volunteering and assisting with the...

Leading Independent Proxy Advisory Firms ISS and Glass Lewis Recommend Revolution Medicines Stockholders Vote “FOR” Proposed Acquisition of EQRx, Inc.

Written by Customer Service on November 1, 2023. Posted in Mergers And Acquisitions.

Revolution Medicines Also Announces the Final Exchange Ratio of 0.1112 REDWOOD CITY, Calif., Nov. 01, 2023 (GLOBE NEWSWIRE) — Revolution Medicines, Inc. (Nasdaq: RVMD), a clinical-stage oncology company developing targeted therapies for RAS-addicted cancers, today announced that leading independent proxy advisory firms, Institutional Shareholder Services Inc. (“ISS”) and Glass Lewis & Co. (“Glass Lewis”), have recommended Revolution Medicines stockholders vote “FOR” the issuance of Revolution Medicines shares in the previously announced all-stock acquisition of EQRx, Inc. at the special meeting of stockholders scheduled for November 8, 2023. In their respective reports, ISS and Glass Lewis view the proposed transaction as favorable to Revolution Medicines stockholders. The acquisition will add the significant...

Sportradar Reports Third Quarter 2023 Results

Written by Customer Service on November 1, 2023. Posted in Earnings Releases And Operating Results.

Delivered 12% revenue, 38% Adjusted EBITDA growth for the third quarterAnnual outlook updated with growth of 19% to 21% for revenue and 29% to 33% for Adjusted EBITDAInitiated a reduction in global workforce as part of ongoing strategic growth initiativesWell positioned for revenue growth and margin expansion ST. GALLEN, Switzerland, Nov. 01, 2023 (GLOBE NEWSWIRE) — Sportradar Group AG (NASDAQ: SRAD) (“Sportradar” or the “Company”), a leading global sports technology company focused on creating immersive experiences for sports fans and bettors, today announced financial results for its third quarter ended September 30, 2023. Carsten Koerl, Chief Executive Officer of Sportradar said: “As the leader in our industry, we aim to consistently deliver value to our clients, partners and shareholders. For 2023 we remain on track to deliver...

EyePoint Pharmaceuticals Reports Third Quarter 2023 Financial Results and Highlights Recent Corporate Developments

Written by Customer Service on November 1, 2023. Posted in Earnings Releases And Operating Results.

– Positive masked safety data update for EYP-1901 in ongoing PAVIA and DAVIO 2 Phase 2 clinical trials as of October 1, 2023 with no drug related ocular or systemic SAEs reported – – Leadership strengthened with the appointment of Stuart Duty to the Board of Directors and the promotion of George Elston to Executive Vice President – – Topline data for Phase 2 DAVIO 2 trial anticipated in December 2023 and Phase 2 PAVIA trial in 2Q 2024 – – Management to host a conference call and webcast today at 8:30 a.m. ET – WATERTOWN, Mass., Nov. 01, 2023 (GLOBE NEWSWIRE) — EyePoint Pharmaceuticals, Inc. (NASDAQ: EYPT), a company committed to developing and commercializing therapeutics to improve the lives of patients with retinal diseases, today announced financial results for the third quarter ended September 30, 2023, and highlighted recent...

ScottsMiracle-Gro Announces Fiscal 2023 Full-Year Results

Written by Customer Service on November 1, 2023. Posted in Earnings Releases And Operating Results.

Full-year total Company net sales of $3.55 billion in line with guidance Free cash flow of $438 million improved $681 million year over year; Company reaffirms $1 billion in free cash flow over two years through Fiscal 2024 Project Springboard cost savings contribute to full year non-GAAP adjusted EBITDA of $447 million Full-year GAAP loss per share of $6.79; adjusted non-GAAP EPS of $1.21MARYSVILLE, Ohio, Nov. 01, 2023 (GLOBE NEWSWIRE) — The Scotts Miracle-Gro Company (NYSE: SMG), the world’s leading marketer of branded consumer lawn and garden as well as indoor and hydroponic growing products, today announced its results for the fourth quarter and fiscal year ended September 30, 2023. The Company reported fiscal 2023 net sales in line with guidance and adjusted non-GAAP earnings exceeding guidance with faster realization of...

Martin Marietta Reports Third-Quarter 2023 Results

Written by Customer Service on November 1, 2023. Posted in Earnings Releases And Operating Results.

Achieved Record Quarterly Consolidated Revenues, Profitability and Margins Aggregates Gross Profit Per Ton Increased 42.4 Percent to $7.89 Robust Earnings Growth Reinforces Benefits of Value-Over-Volume Strategy Raised Adjusted EBITDA Guidance RALEIGH, N.C., Nov. 01, 2023 (GLOBE NEWSWIRE) — Martin Marietta Materials, Inc. (NYSE: MLM) (“Martin Marietta” or the “Company”), a leading national supplier of aggregates and heavy building materials, today reported results for the third quarter ended September 30, 2023. Third-Quarter Highlights (Financial highlights are for continuing operations) Quarter Ended September 30,(In millions, except per share) 2023 2022 % ChangeTotal revenues 1 $ 1,994.1 $ 1,811.7 10.1 %Gross profit $ 676.0 $ 487.8 38.6 %Earnings from operations $ 566.6 $ 405.9 39.6 %Net...

Costamare Inc. Reports Results for the Third Quarter and Nine-Month Period Ended September 30, 2023

Written by Customer Service on November 1, 2023. Posted in Earnings Releases And Operating Results.

MONACO, Nov. 01, 2023 (GLOBE NEWSWIRE) — Costamare Inc. (“Costamare” or the “Company”) (NYSE: CMRE) today reported unaudited financial results for the third quarter (“Q3 2023”) and nine-months ended September 30, 2023. I. PROFITABILITY AND LIQUIDITYQ3 2023 Net Income available to common stockholders of $53.3 million ($0.45 per share). Q3 2023 Adjusted Net Income available to common stockholders1 of $53.9 million ($0.46 per share). Q3 2023 liquidity of $996.9 million2.II. SHARE REPURCHASE PROGRAM TO DATERepurchase of 882,316 common shares, for a total consideration of $10 million, since our Q2 2023 earnings press release. Available funds remaining under the share repurchase program of $30 million for common shares and $150 million for preferred shares.III. DRY BULK OPERATING PLATFORMCostamare Bulkers Inc. (“CBI”)...

Year: 2023

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals